Introduction {#Sec1}
============

Low long-term adherence to drugs by asymptomatic patients with chronic diseases is an important public health issue. Indeed, a report published by the World Health Organisation in 2003 noted that, in developed countries, only 50% of patients with chronic diseases adhered to their recommended treatment regimens \[[@CR1]\]. A community survey performed in Canada has indicated that nonadherence to medication in general was associated with adverse health outcomes such as hospitalisation, emergency department visits or death \[[@CR2]\].

One field of medicine in which treatment adherence is a major issue is antiresorptive therapy to prevent osteoporotic fractures \[[@CR3]\]. A recent expert consensus group in osteoporosis \[[@CR4]\] described adherence as a general term encompassing both compliance and persistence. Compliance was defined as the extent to which a patient acts in accordance with the prescribed interval and dose of a given treatment regimen, whereas persistence was defined as the cumulative time from initiation to discontinuation of therapy. Compliance is frequently assessed by measuring the medication possession ratio (MPR), defined as the ratio between the actual interval between prescription refills and the anticipated interval assuming full compliance \[[@CR5]\].

Oral bisphosphonates are effective treatments of osteoporosis, and several large randomised clinical trials have shown that they can reduce the risk of osteoporotic fractures by an average of 50% \[[@CR6]\]. However, the effectiveness of bisphosphonates is compromised by poor adherence to treatment, since a significant proportion of patients abandon their treatment within 6 months of initiation \[[@CR7]\] and more than half stop treatment within the first year \[[@CR8]--[@CR10]\]. Low adherence reduces the effectiveness of treatment and, in consequence, increases the risk of fracture \[[@CR10]--[@CR13]\] and resulting healthcare use and costs \[[@CR14]\]. A recent Belgian database analysis \[[@CR15]\] showed that the relative reduction in the risk of hip fracture was 60% for women who were persistent with bisphosphonate treatment compared to those who were non-persistent. In addition, for each incremental decrease of 1% in compliance, as measured by the MPR, the risk of hip fracture increased by 0.4%.

For antiresorptive treatments for osteoporosis, public awareness of the risks associated with osteoporosis, the absence of a simple 'read-out' of the efficacy of medication, gastrointestinal side effects and the constraints associated with treatment may all contribute to suboptimal adherence \[[@CR13], [@CR16], [@CR17]\]. In particular, the regimen recommended for bisphosphonates, which requires overnight fasting before medication and the necessity of remaining upright for at least 30 min after having taken the medication, is a major limitation to the acceptability of treatment, especially when treatments need to be taken daily. For this reason, formulations of bisphosphonates allowing weekly and, subsequently, monthly administration have been developed with the aim of reducing the constraints associated with dosing.

Indeed, a number of studies have shown that adherence to weekly administration is superior to that of daily dosing. For example, a study of US prescriptions claims demonstrated a significantly higher MPR (69.2% versus 57.6%; *p* \< 0.0001) and persistence rate (44.2% versus 31.7%; *p* \< 0.0001) associated with the use of once-weekly alendronate compared to once-daily alendronate or risedronate over the 12 months following the initial prescription \[[@CR18]\]. A pharmacy database study in the US also reported that only around one-third of patients taking daily bisphosphonates and around one-half using weekly administration achieved adequate adherence. Such findings have been reiterated in other healthcare systems such as France and the UK \[[@CR19], [@CR20]\].

More recently, monthly administration of ibandronate has been developed with the aim of increasing adherence further \[[@CR21]\]. However, to date, there is little published information on whether adherence to a monthly regimen is indeed superior. The PERSIST study \[[@CR22]\] has compared 6-month persistence rates in women randomised either to monthly ibandronate together with a patient support programme or to weekly alendronate and reported higher persistence rates in the former group (56.6% versus 38.6%; *p* \< 0.0001). However, the relative contributions of the dosing regimen and the patient support programme in improving persistence cannot be identified in this study. On the other hand, a study in the US reported poorer adherence in women receiving monthly ibandronate than in a historical control group treated with weekly risedronate \[[@CR23]\]. This study is difficult to interpret since the two groups were not compared at the same time using the same protocol and because the follow-up period did not start when treatment was initiated. Given the limited amount of comparative data on adherence to monthly bisphosphonate treatment, we have undertaken a pharmacoepidemiological study whose objective was to compare adherence to weekly and monthly bisphosphonate therapy in a cohort of post-menopausal women.

Materials and methods {#Sec2}
=====================

This was a retrospective pharmacoepidemiological study conducted within the context of primary healthcare in France during 2007 using medical claims data from a national prescription database. We examined the data collected during the year preceding and the year following the introduction of ibandronate in France (January 2007).

Data source {#Sec3}
-----------

We used medical claims from the Thales longitudinal prescription database. Thales is a computerised network of 1,200 general practitioners (GPs) who contribute exhaustive anonymous data on patient consultations and treatment to a centralised electronic database, allowing subsequent follow-up of outcomes. Analyses performed using this database have been approved by the *Commission Nationale de l\'Informatique et des Libertés*.

GPs participating in the Thales network are selected to be representative of the French GP population according to three main criteria, namely, geographical area, age and gender. Activity and prescription habits of the panel have also been compared a posteriori with national data and shown to be representative \[[@CR24]\]. The database includes routinely collected records for \>1.6 million patients. Since 2005, each patient is required by law to have a single referent GP in order to limit medical roaming and multiple consultations for the same reason. Patient data collected by GPs since 2005 can thus be considered exhaustive and non-redundant.

For each patient, information on disease status and medication prescription is entered directly into the database by the physician at the time of the consultation. No information as to the reasons for making individual diagnostic or prescription choices is, however, provided. The disease status is encoded using terms from a specific thesaurus of symptoms and disease entities adapted from the International Classification of Diseases (ICD-10) system. Prescription data contain the dispensed drug name (commercial and international common denomination), the Anatomical Therapeutic Chemical (ATC) classification category, dose regimens and prescription duration.

Study population {#Sec4}
----------------

We identified all female patients in the Thales database, aged over 45 years who had received a first prescription of either a weekly or a monthly bisphosphonate treatment between January 2007 (date of introduction of ibandronate in France) and the end of 2007. The index date for the analysis was the date of the initial prescription. These patients were followed up prospectively until January 2008 to evaluate treatment adherence. A retrospective analysis was also performed covering the period from January 2006 to January 2007 in order to identify subjects who had been prescribed any other osteoporosis treatment (bisphosphonates, selective oestrogen receptor modulators or strontium ranelate) during the 12-month period prior to the index prescription, who were excluded. In order to ensure completeness of data, patients were also required to have consulted their GP at least twice a year for any reason during the retrospective and prospective follow-up periods (January 2006--January 2008). In order to restrict the analysis to patients who discontinued treatment definitively, we excluded any women who subsequently switched treatment from one bisphosphonate to another during the follow-up period. Study subjects were then assigned to one of two cohorts on the basis of their treatment administration regimen, namely, a weekly (risedronate 35 mg or alendronate 70 mg with or without vitamin D) or a monthly (ibandronate 150 mg) cohort. Within the weekly cohort, women receiving alendronate and those receiving risedronate were pooled, on the basis that the two bisphosphonates present side effect profiles and risks of discontinuation \[[@CR25]\].

Data collection {#Sec5}
---------------

Data were collected on demographic and clinical variables at the time of the index prescription. Information on comorbidities and other medication use or clinical examinations at the time of the index prescription and during the follow-up period were recorded for each patient. All prescriptions for bisphosphonates during the follow-up period were identified. Information on fracture history at inclusion and incident fractures during the follow-up period was also retrieved from the database. Information on fracture site and radiological evaluation was, however, not systematically available.

Outcome measures {#Sec6}
----------------

The outcome measures of the study were MPR and persistence. MPR was defined as the duration of all filled prescriptions divided by the follow-up period. Persistence was measured by the time from initiation of therapy to discontinuation. As required for persistence analysis, a limit on the number of days allowed between refills, the permissible gap (PG), was prespecified. Patients who stopped their treatment for a duration longer than the PG were considered to have discontinued, even if they subsequently restarted treatment. In many previous studies, the PG applied to weekly bisphosphonates was specified empirically at 30 days \[[@CR9], [@CR26]--[@CR28]\]. Cramer et al. \[[@CR5]\] recently proposed a less arbitrary method based on the pharmacological properties of the drug and the treatment situation in which the PG definition should take into account the maximum allowable period for which patients could go untreated without anticipating reduced or suboptimal outcomes. As specified in the product labelling, the recommended acceptable dosing window for monthly ibandronate (21 days) is 15 days longer than that of weekly bisphosphonates (6 days). For this reason, a prespecified PG of 45 days for the monthly regimen and of 30 days for the weekly regimen was considered acceptable, as previously implemented in a US database analysis \[[@CR29]\]. We also performed a sensitivity analysis in order to test the influence of the definition of PG on the persistence results in which an identical PG of 30, 45 or 60 days was allowed for both formulations.

Statistical analysis {#Sec7}
--------------------

The demographic and clinical characteristics of patients included in the two cohorts were compared using the *χ*^2^ test or Fisher's exact test for categorical variables and the Kruskal--Wallis test for continuous variables.

Persistence rates were evaluated using Kaplan--Meier survival analysis and compared between the two cohorts using the log-rank test in a Cox proportional hazards model. For MPR, the two cohorts were described by mean MPR values and by distribution of patients across MPR classes. This analysis was performed on the entire study population.

Since the profiles of patients in the weekly and monthly cohorts were potentially different and confounding factors could thus contribute to the difference in persistence and in MPR between the two cohorts, these were taken into account by constructing a propensity score \[[@CR30]\]. This score included all demographic, clinical and treatment variables recorded in the database and was calculated using multivariate logistic regression. Each patient was attributed a propensity score that represented the probability of receiving monthly rather than weekly bisphosphonate treatment with respect to the pattern of potential confounding factors presented. The cohorts were compared by means of hazard ratios for persistence and least squares means for compliance. These parameters are presented with their 95% confidence intervals (95%CI), both unadjusted and after adjustment by the propensity score. With respect to persistence, a sensitivity analysis was performed in order to determine the influence of the definition of the permissible gap on the results obtained.

All demographic and clinical variables were tested for their association with MPR and persistence using multivariate logistic regression analysis. This analysis was restricted to women for whom at least 6 months\' follow-up was available since the initial prescription of a bisphosphonate. For persistence, the dependent variable to be explained was reaching a persistence of at least 6 months, and for MPR, reaching an MPR of at least 68%. These thresholds were chosen since they had been identified as the best predictors of fracture risk in a previous case--control analysis of women treated with bisphosphonates in the Thalès database \[[@CR31]\]. Variables were selected serially in an ascending manner, with a cut-off probability threshold of 0.05 at each step. The variables retained in the stepwise model were then entered into a final multivariate logistic regression in order to compute odds ratios.

All analyses were performed using SAS® software version 8.2 (SAS, Cary, USA) on Windows.

Results {#Sec8}
=======

Participating investigators {#Sec9}
---------------------------

In the Thales database, 1,073 physicians provided patients to the study, of whom 541 prescribed both monthly and weekly regimens, 123 only monthly regimens and 409 only weekly regimens. These three groups of physicians did not differ with respect to age, gender or place of practice in France (data not shown).

Study sample {#Sec10}
------------

A total of 3,157 women were prescribed a weekly or monthly bisphosphonate treatment for the first time during the reference period (January 2007 to January 2008). Of these, 63 women were under 45 years and were excluded. In addition, 104 subjects (82 in the weekly group and 22 in the monthly group) subsequently switched to another bisphosphonate treatment and were also excluded from the study sample (Fig. [1](#Fig1){ref-type="fig"}). The analysis was thus performed on the remaining 2,990 women, of whom 1,989 received weekly bisphosphonate (581 alendronate and 1,408 risedronate) and 1,001 monthly ibandronate. Given that the demographic and clinical characteristics of women receiving alendronate and risedronate were comparable (data not shown), these two groups were not analysed separately but pooled in a single weekly regimen group. Fig. 1Flowchart illustrating selection of patients evaluated in the database. *RIS* risedronate, *ALEN* alendronate

In the two cohorts, data was available over at least 6 months of follow-up since the initial prescription of a bisphosphonate for a total of 1,889 women. This subgroup was used for the analysis of variables associated with good adherence.

Patient characteristics in the two treatment cohorts {#Sec11}
----------------------------------------------------

The demographic and clinical characteristics of the study sample at the time of the index prescription are presented in Table [1](#Tab1){ref-type="table"}. Patients receiving monthly ibandronate were younger than patients in the weekly cohort and had less frequent osteoporotic fractures before treatment initiation. At initiation, bone densitometry had been performed more frequently in the monthly cohort than in the weekly cohort (*p* = 0.003), but there was no difference in the two cohorts for bone mass densitometry (BMD) assessments during the follow-up. Table 1Demographic and clinical variables in the study sample Monthly ibandronate (*N* = 1,001)Weekly bisphosphonates (*N* = 1,989)*p* valueAge (years)68.8 ± 10.370.4 ± 10.3\<0.001\*BMI (kg/m^2^)24.9 ± 4.424.9 ± 4.80.890Height (cm)158 ± 7158 ± 60.128Weight (kg)62.5 ± 11.662.2 ± 12.30.375Known smoker, *n* (%)35 (3.5)74 (3.7)0.836Known alcohol problem, *n* (%)26 (2.6)52 (2.6)1.000Previous osteoporotic fracture, *n* (%)325 (32.5)810 (40.7)\<0.001\*BMD availability, *n* (%) Before treatment initiation186 (18.6)288 (14.5)0.003\* After treatment initiation32 (3.2)61 (3.1)0.845Comorbidities, *n* (%) Any875 (87.4)1,729 (86.9)0.481 ≥4 comorbidities173 (17.3)368 (18.5)0.421Comedications^a^0.041\* Number of ATC classes7.7 ± 4.57.3 ± 4.2 ≤7 classes, *n* (%)538 (53.7)1,130 (56.8) \>7 classes, *n* (%)463 (46.3)859 (43.2)Quantitative variables are presented as mean values±standard deviations and categorical variables as absolute patient numbers (percent)*BMI* body mass index, *BMD* bone mass densitometry\**p* \< 0.10, significant differences between the two treatment regimens^a^Based on osteoporosis treatment initiation and prior 6 months

The most common comorbidities were arterial hypertension (44.5%), other rheumatic diseases (31.5%), malignant neoplasms (28.0%) and neurological diseases (27.1%). The only condition whose distribution differed significantly between the monthly and weekly cohorts was rheumatoid arthritis (1.6% versus 2.7%, respectively), although this was only reported in 70 patients overall.

The most frequently prescribed comedication classes were tranquillisers (34.7%), anti-inflammatory and anti-rheumatic drugs (31.8%) and lipid-reducing agents (29.5%). No difference in prescription rates between cohorts was observed for these medication classes. However, the prescription of 13 other comedication classes did differ significantly between the two cohorts, notably drugs used for functional gastrointestinal disorders (19.3% in the monthly group and 16.3% in the weekly group), systemic antibacterial drugs (23.9% and 19.3%, respectively) and antineoplastic drugs (0.3% and 1.2%, respectively). In addition, calcium or vitamin D supplementation (53.0% in the monthly group versus 57.6% in the weekly group) and other mineral supplementation (56.1% in the monthly group versus 60.9% in the weekly group) were more frequently used in the weekly regimen group (*p* = 0.017 and *p* = 0.013, respectively).

Patient follow-up {#Sec12}
-----------------

Following the index prescription, patients treated with monthly ibandronate were followed up for an average of 189 days and those treated with weekly bisphosphonates for an average of 197 days. In the weekly group, 14.0% of patients had been followed up for less than 3 months, compared to 17.9% in the monthly group. The corresponding proportions of patients followed up for more than 9 months were 38.0% for weekly treatment and 34.0% for monthly treatment. The mean treatment cover of an individual prescription was 69 days in the weekly cohort and 75 days in the monthly cohort, with 39.5% and 46.9%, respectively, of prescriptions covering at least 3 months.

Adherence to bisphosphonate treatment {#Sec13}
-------------------------------------

Survival analysis demonstrated treatment persistence to be significantly longer (*p* \< 0.0001) in the monthly bisphosphonate cohort than in the weekly bisphosphonate cohort (Fig. [2](#Fig2){ref-type="fig"}). Persistence rates at 6 months in the two cohorts were 57.3% and 45.7% and fell to 47.5% and 30.4%, respectively, at 12 months. After propensity score adjustment, women in the monthly group were 37% more likely to persist than those in the weekly group (Table [2](#Tab2){ref-type="table"}). Fig. 2Kaplan--Meier analysis of treatment discontinuation with bisphosphonate. *Thick line* monthly ibandronate cohort, *thin line* weekly bisphosphonates. A permissible gap of 45 days for monthly ibandronate and 30 days for weekly bisphosphonates was allowed in this analysisTable 2Median persistence duration and associated hazard ratios with bisphosphonate treatments for the base case analysis and for different definitions of the permissible gapPersistence modelsMedian persistence duration (days)Hazard ratios (95%CI)Monthly ibandronate (*N* = 1,001)Weekly BP (*N* = 1,989)UnadjustedAdjusted^a^Base case2651690.63\* (0.56--0.71)0.63\* (0.56--0.72) Monthly regimen: PG = 45 days Weekly regimen: PG = 30 daysSensitivity analyses Both PG of 30 days1841690.76\* (0.68--0.85)0.77\* (0.69--0.86) Both PG of 45 days2652110.77\* (0.68--0.87)0.78\* (0.69--0.89)*PG* permissible gap\**p* \< 0.0001^a^Cox proportional hazard model adjusted by propensity score

Sensitivity analyses were performed to assess the impact of the attributed PG on the persistence rates obtained. If an identical PG was allowed for both treatment regimens, the difference in persistence at 1 year was reduced but remained significantly higher (*p* \< 0.0001) for the monthly regimen. If a PG of 30 days was allowed, persistence rates over 12 months were 38.0% for the monthly regimen and 30.4% for the weekly regimen (adjusted HR = 0.77, 95%CI = 0.69--0.86, *p* \< 0.0001). If 45 days were allowed for both regimens, the rates were 47.5% and 40.5%, respectively (adjusted HR = 0.78, 95%CI = 0.69--0.89, *p* \< 0.0001).

Of the non-persistent patients, certain women discontinued treatment definitively whilst others resumed their treatment at a later date following a 'drug holiday'. In the base case scenario, 29.8% \[95%CI = 25.5% to 34.1%\] of non-persistent women in the monthly ibandronate cohort (13.0% of all women in the cohort) and 31.3% \[95%CI = 28.5% to 34.1%\] in the weekly bisphosphonate cohort (16.2% of the entire cohort) resumed treatment after a 'drug holiday' which extended beyond the permissible gap. These proportions were not significantly different between the two cohorts.

Similarly, compliance as measured by the mean MPR was significantly lower (*p* \< 0.001) in the weekly cohort (Table [3](#Tab3){ref-type="table"}), with 65.8% of subjects presenting an MPR of ≥80% compared to 74.1% in the monthly ibandronate cohort. Table 3Compliance to bisphosphonate treatments over 12 monthsMPRMonthly ibandronate (*N* = 1,001)Weekly bisphosphonates (*N* = 1,989)*p* valueMean±SD (95% CI)84.5 ± 23.0 (83.1--85.9)79.4 ± 26.7 (78.2--80.5)\<0.001Adjusted^a^ mean±SD (95%CI)84.5 ± 25.9 (82.9--86.2)79.3 ± 25.7 (78.2--80.4)\<0.001 \<20%20 (2.0%)98 (4.9%)\<0.001 20--\<40%61 (6.1%)169 (8.5%) 40--\<60%85 (8.5%)179 (9.0%) 60--\<80%93 (9.3%)234 (11.8%) ≥80%742 (74.1%)1,309 (65.8%)*MPR* medication possession ratio^a^General linear model adjusted by propensity score

Determinants of persistence and compliance to bisphosphonate treatment {#Sec14}
----------------------------------------------------------------------

Variables independently associated with persistence and compliance with bisphosphonate treatment were identified using stepwise logistic regression (Table [4](#Tab4){ref-type="table"}). Each regression retained five variables, of which four were common to both models. Availability of baseline BMD data, monthly treatment regimen and use of calcium or vitamin D supplementation were associated with better persistence and higher compliance, whereas a diagnosis of rheumatoid arthritis was associated with worse persistence and compliance. A diagnosis of neurological disease was associated with better persistence and the use of topical products for joint and muscular pain (ATC class: M02) with poor compliance only. Table 4Determinants of persistence (≥6 months) and compliance (MPR ≥68%) Odds ratio95%CIDeterminants of persistence BMD available1.84\*1.43--2.37 Monthly regimen1.57\*1.29--1.91 Neurological disorder1.30\*\*\*1.06--1.59 Calcium or vitamin D intake1.28\*\*1.06--1.54 Rheumatoid arthritis0.37\*\*0.19--0.73Determinants of compliance Bone mass densitometry available1.55\*\*1.18--2.04 Calcium or vitamin D intake1.36\*\*1.12--1.65 Monthly regimen1.28\*\*\*1.04--1.58 Topical products for joint and muscular pain0.73\*\*0.58--0.92 Rheumatoid arthritis0.45\*\*0.25--0.81Data are presented as odds ratios with their 95%CI determined by stepwise logistic regression\**p* \< 0.0001; \*\**p* \< 0.01; \*\*\**p* \< 0.05

Fracture incidence {#Sec15}
------------------

During the follow-up period, a lower proportion of patients in the monthly cohort (20 women; 2.0%) reported an incident fracture than in the weekly cohort (125 women; 6.3%). This difference remained significant after adjustment for the propensity score, which included major known risk factors for fracture, such as age and prior fracture (HR = 0.69, 95%CI = 0.54--0.89, *p* = 0.0043).

Discussion {#Sec16}
==========

This retrospective pharmacoepidemiological study using a large primary care database showed that adherence to a monthly bisphosphonate treatment regimen is higher than that to weekly regimens in post-menopausal women. This association could be detected after adjustments for all other available confounding factors. We observed that patients treated with a monthly regimen were 37% less likely to be non-persistent and were more compliant, with a 5% higher absolute MPR, than women treated with weekly regimens.

Optimising treatment adherence to bisphosphonates is crucial to minimising fracture risk \[[@CR32]\]. Indeed, several studies have shown that adherence to treatment is the major determinant of its efficacy. For example, Siris et al. \[[@CR33]\] reported that patients with an MPR \>80% who were persistent (no permissible gap in refills for \>30 days over 24 months) presented a reduction in fracture risk of 20% to 45% compared to patients who did not meet these adherence goals. A patient registry study in The Netherlands \[[@CR13]\] revealed that non-compliant bisphosphonate use (MPR \<80%) was associated with a 45% increase in fracture risk compared to compliant use and that patients with an MPR \<20% presented an increased fracture risk of 80% compared to those with an MPR ≥90%. Similarly, in a Canadian healthcare claims database \[[@CR34]\], women with an MPR \<80% presented a relative risk of hip fracture of 1.28 compared with more compliant women. In these studies, the thresholds for optimal MPR were defined a priori. In a recent case--control study, we attempted to determine empirically the thresholds of persistence and MPR associated with optimal protection against fracture \[[@CR31]\] and found that a threshold MPR of 68% was the most discriminant for fracture protection. Fracture risk was reduced by 51% in women who achieved this threshold compared to less compliant women. Concerning persistence, the optimal threshold was at least 6 months of drug therapy.

In this context, it is possible that the increased compliance and persistence associated with the use of monthly administration observed in the present study could provide a clinically relevant reduction in the risk of fracture. Indeed, the observed fracture rates were significantly lower (*p* = 0.0043) in the monthly treatment group (2% versus 6.3% in the weekly treatment group) and this remained significant after adjustment for the propensity score. This score included many important fracture risk factors, such as BMI, previous fracture history and age, but not all of these (for example, family history of osteoporotic fracture and bone mass density were not included). Nonetheless, prospective randomised comparative trials would be useful to quantify any correlation between adherence and fracture outcome for different bisphosphonate treatment regimens, and the observation of the current study should only be regarded as hypothesis-generating.

Even with monthly administration, adherence to bisphosphonate treatment remains largely suboptimal, and strategies are needed to improve this. A number of methods to improve persistence to oral bisphosphonates have indeed been suggested. For example, offering bone densitometry to women treated with bisphosphonates has been found to be associated with a lower probability of discontinuation \[[@CR35]\], although there is no evidence that the BMD change, if any, is directly related to anti-fracture effectiveness. Moreover, the impact of offering densitometry may be limited, since the largest loss of patients to treatment occurs within the first 6 months of prescription, an interval in which bone densitometry is neither recommended nor proposed. Others have suggested the utility of biochemical markers to provide patients with feedback on treatment effectiveness \[[@CR36]\], but such markers are not determined in routine clinical practice. Improving patient communication on the importance of treatment and use of reminder systems is clearly important. For example, Briot et al. \[[@CR37]\] reported that osteoporotic women starting therapy with a parathyroid hormone analogue who enrolled in an education and follow-up programme could achieve 15-month persistence rates \>80%.

It should be noted that non-persistence, as defined in this and other studies, is not necessarily equivalent to treatment discontinuation, as patients may lapse and then resume treatment after a 'drug holiday' of variable duration. Given the long half-life of bisphosphonates in bone tissue, such women may continue to gain some benefit from their treatment even if they go on 'drug holidays'. Although such behaviour was not studied in detail here and would merit evaluation in a study with considerably longer follow-up duration, it is unlikely that the differences in persistence observed in our study could be accounted for by 'drug holidays', as the proportion of women who did this was relatively low and similar between the two cohorts.

An important potential confounding factor in any comparison of adherence between different treatment regimens is that patients prescribed one or other regimen may be different. Indeed, in the present study, we found, for example, that women prescribed monthly bisphosphonates tended to be younger and less likely to have already experienced an osteoporotic fracture. In contrast, they were more likely to have undergone bone densitometry. This probably relates to the fact that the women could either receive a diagnosis on the basis of BMD or on the basis of fracture. Since the proportion of women with previous fractures was lower, they were de facto more likely to have received a diagnosis on the basis of low BMD, accounting for the higher use of bone densitometry in this group. Women in the monthly group were also more frequently receiving multiple comedications, which may have been an incentive for their physicians to prescribe them less frequently administered bisphosphonates.

These factors may themselves influence treatment adherence and it is important that they be taken into account in any adherence study. For this reason, we performed multivariate analysis of our adherence data in order to determine the influence of the treatment regimen independently of that of such confounding factors. Both for MPR and persistence rates, we found that the treatment regimen was a highly significant independent determinant of both MPR and persistence.

With respect to other variables independently associated with persistence or compliance, our findings were broadly consistent with previous reports. The influence of bone densitometry on reinforcing adherence has been a consistent finding of previous studies \[[@CR16], [@CR35]\], but is difficult to interpret here as the outcome of the evaluation (T-score) was not available. Calcium or vitamin D supplementation has previously been reported to be associated with better compliance and improved fracture outcome in the ICARO study \[[@CR38]\]. Such dietary supplementation may also be indicative of higher motivation. Likewise, patients with a neurological disorder (notably epilepsy, Alzheimer or Parkinson's disease) were more persistent than others, which may reflect awareness of physicians about the high risk of fracture in such patients \[[@CR39]--[@CR41]\], as well as, for patients with epilepsy, a history of treatment for which good adherence is critical. Topical products for joint and muscular pain mainly correspond to non-steroidal anti-inflammatory drugs. Those drugs could be prescribed for their analgesic effects on pain related to fractures, such as back pain with vertebral fractures. Relief of these symptoms may also lead patients to be less adherent to treatment of osteoporosis. Even though the absolute number of patients was low (70 patients in all), a significant association between a diagnosis of comorbid rheumatoid arthritis and low MPR and poor persistence was observed. The interpretation of this finding is unclear, but in the absence of further information on rheumatoid pathology, it merits exploration in a dedicated study. It is noteworthy that it has been previously reported that patients with rheumatoid arthritis taking oral glucocorticoids did not routinely undergo bone densitometry or receive prescription medications for osteoporosis \[[@CR42]\].

An important determinant of the validity of our findings is the representativity of the source data. The Thales database has been demonstrated to be a reliable source of information in numerous previous studies in rheumatology \[[@CR19], [@CR24]\] and in other fields of medicine \[[@CR43]--[@CR46]\]. In addition, the proportions of patients with various comorbidities in our study sample are consistent with the known prevalence of these diseases in women over 45.

This study has several limitations. Some of these are linked to the use of a primary care registry as the data source. The use of such databases for pharmacoepidemiological studies has become popular of recent years, since it allows access to information on a large number of patients gathered in real-world conditions \[[@CR3], [@CR47]\]. However, it is not possible to ascertain ascribed diagnoses and to ensure that these are exhaustive. Moreover, data on many important variables that may influence the risk of fracture and the uptake of treatment, such as family history and lifestyle factors, are not available. In our study, patients who switched treatment have been excluded from the analysis, and this may limit the extent to which the findings can be generalised to all women starting an antiresorptive therapy with bisphosphonates. Such women may switch to a treatment that they consider more acceptable, with which they may be more compliant. In our study, the proportion of women who switched treatments within the following year was 3%, lower than switch rates reported in previous studies \[[@CR35]\] and is unlikely to have introduced significant bias. However, the adherence of switchers to their new treatment merits a dedicated study. Finally, the definition of an acceptable prescription refill gap for determining persistence rates in the study was arbitrary, even though this definition is known to exert a crucial influence on the observed persistence. We have attempted to control for the influence of confounders on the observed differences between the monthly and weekly regimens by using propensity scoring, but it is clearly possible that unidentified confounders for which data were not collected may play a role. It should be noted that a criterion for inclusion was that women should have consulted their GP during the reference period, which may de facto enriched the study population in more adherent patients. However, such a bias is in principle non-differential between the two groups.

The study also presents a number of strengths. These include the representativity of the study sample with respect to primary care in France. In addition, multivariate analysis was performed to take into account the influence of potential confounding factors on the relationship between treatment regimen and adherence. The fact that the confounding factors identified were consistent with known determinants of adherence supports the face validity of the model. In addition, sensitivity analyses were performed to determine the influence of the definition of the permissible gap on the findings. A significant relationship between treatment regimen and adherence was found with all hypotheses, supporting the robustness of this relationship.

In conclusion, this study suggests that adherence to bisphosphonates is superior using a monthly treatment regimen than using a weekly one. This difference would be expected to have major repercussions on fracture protection in osteoporotic women using such treatments. However, adherence remains suboptimal and other interventions to improve adherence need to be identified and implemented.
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